Related Experiment Video
Updated: Jun 3, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Lung cancer andCYP1A1 orGSTM1 polymorphisms.
Tsunehiro Oyama1, Norio Kagawa, Yong-Dae Kim
1Departments of Environmental Health, University of Occupational and Environmental Health, 807, Kitakyushu, Japan.
Environmental Health and Preventive Medicine
|March 25, 2011
Summary
Genetic variations in GSTM1 and CYP1A1 genes are linked to lung cancer risk. Studying these polymorphisms can help predict individual cancer susceptibility and guide prevention strategies for environmental carcinogen exposure.
Area of Science:
- Biochemistry
- Genetics
- Cancer Research
Background:
- Chemical carcinogens are activated by Phase I enzymes (e.g., cytochromes P450) and detoxified by Phase II enzymes (e.g., glutathione-S-transferases - GST).
- Genetic polymorphisms in genes encoding these enzymes, specifically GSTM1 and CYP1A1, are increasingly studied for their role in disease susceptibility.
Purpose of the Study:
- To review the current understanding of polymorphisms in the GSTM1 and CYP1A1 genes.
- To explore the association between these genetic variations and susceptibility to lung cancer.
Main Methods:
- Literature review of studies investigating GSTM1 and CYP1A1 gene polymorphisms.
- Analysis of the relationship between these polymorphisms and lung cancer risk.
Main Results:
- Polymorphisms in GSTM1 and CYP1A1 genes are associated with altered lung cancer susceptibility.
- These polymorphisms serve as potential biomarkers for assessing environmental carcinogen exposure and burden.
Conclusions:
- Investigating GSTM1 and CYP1A1 polymorphisms offers insights into individual lung cancer risk prediction.
- Understanding these genetic variations is crucial for developing targeted cancer prevention strategies.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:33Cancer-Critical Genes I: Proto-oncogenes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...